OctoPlus announces promising results for Locteron Phase IIa clinical study
OctoPlus N.V. announced positive initial results of the ongoing SELECT-1 Phase IIa study with its lead product Locteron(TM) , a controlled release interferon alfa for the treatment of chronic hepatitis C (HCV). In the 12-week Phase IIa study, the combination of the highest dose of Locteron evaluated until now, and the antiviral drug ribavirin, achieved an early virologic response (EVR) in 100% of the hepatitis C patients treated. The study reported an overall strong antiviral response at twelve weeks and an adverse event profile that shows substantial tolerability improvement compared to other interferons, either on the market or in development. OctoPlus is co-developing Locteron with its partner Biolex Therapeutics.
These initial results are from the first three cohorts (160, 320 and 480 ug); treatment of the fourth and last cohort (640ug) is ongoing. Complete and final study results will be reported in the fourth quarter of this year.
Locteron combines OctoPlus' proprietary PolyActive(TM) drug delivery technology with BLX-883, a recombinant alfa interferon produced by OctoPlus' co-development partner Biolex Therapeutics in its patented LEX System(SM). Locteron is produced in OctoPlus' cGMP manufacturing facilities in Leiden, the Netherlands.
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.